8-K: Fortrea Reports Mixed Third Quarter Results Amidst Ongoing Separation

Fortrea's third quarter results show a decrease in revenue year-over-year but an increase in adjusted EBITDA sequentially, alongside a strong book-to-bill ratio.

Summary

• Fortrea reported a third-quarter revenue of $674.9 million, down from $713.8 million in the same period last year.
• The company experienced a GAAP net loss of $18.5 million, compared to a loss of $16.1 million in the third quarter of 2023.
• Adjusted EBITDA for the quarter was $64.2 million, a decrease from $68.2 million year-over-year, but a 16.3% increase sequentially.
• The book-to-bill ratio was 1.23x for the quarter, resulting in a 1.15x trailing 12-month book-to-bill ratio.
• Year-to-date revenue was $1,999.4 million, compared to $2,132.8 million in 2023.
• Year-to-date GAAP net loss was $197.6 million, a significant decrease from a net income of $16.9 million in 2023.
• Year-to-date adjusted EBITDA was $146.5 million, down from $186.9 million in 2023.
• The company's backlog increased to $7,571 million as of September 30, 2024.
• Full-year 2024 revenue guidance has been updated to $2,700 million to $2,725 million, while adjusted EBITDA guidance remains unchanged at $220 million to $240 million.
• Operating cash flow for the nine months ended September 30, 2024, was $245.7 million, and free cash flow was $217 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the book-to-bill ratio is positive and there is sequential improvement in EBITDA, the year-over-year declines in revenue and profitability, along with the ongoing challenges of the spin-off, temper the overall outlook.

Positives

• The book-to-bill ratio of 1.23x for the quarter indicates strong new business wins.
• Adjusted EBITDA increased by 16.3% sequentially, showing improved profitability compared to the previous quarter.
• The company has made significant progress in its post-spin separation, migrating over 90% of IT applications and servers.
• The backlog increased to $7,571 million, suggesting future revenue potential.
• Operating cash flow for the nine months ended September 30, 2024, was $245.7 million, and free cash flow was $217 million.

Negatives

• Third-quarter revenue decreased to $674.9 million from $713.8 million in the same period last year.
• The company reported a GAAP net loss of $18.5 million for the third quarter, compared to a $16.1 million loss in the third quarter of 2023.
• Adjusted EBITDA decreased year-over-year, from $68.2 million to $64.2 million.
• Year-to-date GAAP net loss was $197.6 million, a significant decrease from a net income of $16.9 million in 2023.
• Year-to-date adjusted EBITDA was $146.5 million, down from $186.9 million in 2023.

Risks

• The company faces risks related to the spin-off from Labcorp, including potential delays in realizing expected benefits.
• Fortrea is dependent on third parties for critical services during and after the transition period.
• The establishment of new accounting and management systems could cost more or take longer than anticipated.
• Macroeconomic conditions could lead to customer defaults or cancellations.
• The company's backlog may not fully translate into future revenue.
• There is a risk of underpricing contracts or overrunning cost estimates.
• The company's international operations and currency fluctuations pose additional risks.

Future Outlook

Full-year 2024 revenue guidance has been updated to $2,700 million to $2,725 million. Full-year 2024 adjusted EBITDA guidance remains unchanged at a range of $220 million to $240 million.

Management Comments

• Tom Pike, chairman and CEO of Fortrea, stated that the company had a solid quarter of execution.
• He noted that the book-to-bill ratio for the quarter was a nice mix of both large pharma and biotech awards.
• He also mentioned that the company has continued to make strong progress in the post-spin separation from its former parent.

Industry Context

Fortrea operates in the competitive contract research organization (CRO) industry, where companies provide clinical development solutions to the life sciences sector. The results reflect the challenges of a recent spin-off and the need to establish independent operations while maintaining growth and profitability. The book-to-bill ratio is a key metric in this industry, and Fortrea's 1.23x indicates a healthy demand for its services.

Comparison to Industry Standards

• Fortrea's book-to-bill ratio of 1.23x for the quarter is a positive sign, indicating strong demand for its services, and is comparable to other leading CROs such as IQVIA and PPD.
• However, the year-over-year decrease in revenue and adjusted EBITDA suggests that Fortrea is still facing challenges in its transition period, which is not uncommon for companies undergoing a spin-off.
• Compared to IQVIA, which has a more diversified service offering, Fortrea's focus on clinical development may make it more susceptible to fluctuations in that specific market segment.
• PPD, another major player, has also reported mixed results recently, indicating that the CRO industry is facing some headwinds, including macroeconomic uncertainty and customer consolidation.
• Fortrea's adjusted EBITDA margin of approximately 9.5% for the quarter is lower than some of its peers, suggesting room for improvement in operational efficiency.

Stakeholder Impact

• Shareholders may be concerned about the year-over-year decline in revenue and profitability.
• Employees may be affected by ongoing restructuring and cost-cutting measures.
• Customers may be impacted by the company's transition and any potential service disruptions.
• Suppliers and creditors may be monitoring the company's financial health and ability to meet its obligations.

Next Steps

• Fortrea will host its quarterly conference call on November 8, 2024, to review its third-quarter performance.
• A replay of the conference call and a supplemental slide presentation will be available on the Fortrea Investor Relations website.

Key Dates

Keywords

Contract Research Organization, CRO, Clinical Trials, Pharmaceutical, Biotechnology, EBITDA, Revenue, Backlog, Book-to-bill, Spin-off